Comparative efficacy of TAS-102 and chemotherapy rechallenge in the third-line setting and beyond in patients with advanced colorectal cancer: A retrospective study.

被引：0
|
作者：
Alanazi, Rakan
Alotaibi, Khalid
Ali, Murtada Mohamed
Abushara, Ahmed
Albahrani, Zainab
Alsehali, Afrah
Almesfir, Reem
Alsubaie, Razan
Alkaiyat, Mohammad
Shehata, Husam
Sabatin, Fouad
Algarni, Mohammed Ahmed
机构：
[1] Minist Natl Guard Hlth Affairs, Oncol Dept, Riyadh, Saudi Arabia
[2] Minist Natl Guard Hlth Affairs, Riyadh, Saudi Arabia
[3] Minist Natl Guard Hlth Affairs, Dept Oncol, Riyadh, Saudi Arabia
[4] Minist Natl Guard Hlth Affairs, Dept Oncol, King Abdulaziz Med City, Riyadh, Saudi Arabia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2025年 / 43卷 / 4_SUPPL期
关键词：
D O I：
10.1200/JCO.2025.43.4_suppl.78
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
78
引用
收藏
页码：78 / 78
页数：1
相关论文
共 50 条
  • [1] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Mouri, Takashi
    Ishida, Kota
    Matsumoto, Nori
    Akiba, Tadashi
    Yanaga, Katsuhiko
    ANTICANCER RESEARCH, 2018, 38 (04) : 2419 - 2422
  • [2] Usefulness of TAS-102 as Third-line Chemotherapy for Metastatic Colorectal Cancer
    Kawahara, Hidejiro
    Yanaga, Katsuhiko
    CANCER SCIENCE, 2018, 109 : 601 - 601
  • [3] The combination of TAS-102 and bevacizumab as the third-line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study).
    Kosugi, Chihiro
    Kamiyama, Hirohiko
    Yoshida, Yoichiro
    Yoshida, Hiroshi
    Ishibashi, Keiichiro
    Ihara, Keisuke
    Takahashi, Makoto
    Kuramochi, Hidekazu
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Fukazawa, Atsuko
    Matsuda, Akihisa
    Yamaguchi, Satoru
    Ishida, Hideyuki
    Hasegawa, Suguru
    Yamada, Takeshi
    Narushima, Kazuo
    Shuto, Kiyohiko
    Sakamoto, Kazuhiro
    Koda, Keiji
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [4] Efficacy of Chemotherapy Rechallenge Versus Regorafenib or Trifluridine/Tipiracil in Third-Line Setting of Metastatic Colorectal Cancer: A Multicenter Retrospective Comparative Study
    Bazarbashi, Shouki
    Alkhatib, Radwan
    Aseafan, Mohamed
    Tuleimat, Yasmin
    Abdel-Aziz, Nashwa
    Mahrous, Mervat
    Elsamany, Sherif
    Elhassan, Tusneem
    Alghamdi, Mohammed
    JCO GLOBAL ONCOLOGY, 2024, 10
  • [5] Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
    Yoichiro Yoshida
    Takeshi Yamada
    Hirohiko Kamiyama
    Chihiro Kosugi
    Keiichiro Ishibashi
    Hiroshi Yoshida
    Hideyuki Ishida
    Satoru Yamaguchi
    Hidekazu Kuramochi
    Atsuko Fukazawa
    Hiromichi Sonoda
    Kazuhiko Yoshimatsu
    Akihisa Matsuda
    Suguru Hasegawa
    Kazuhiro Sakamoto
    Toshiaki Otsuka
    Keiji Koda
    International Journal of Clinical Oncology, 2021, 26 : 111 - 117
  • [6] Combination of TAS-102 and bevacizumab as third-line treatment for metastatic colorectal cancer: TAS-CC3 study
    Yoshida, Yoichiro
    Yamada, Takeshi
    Kamiyama, Hirohiko
    Kosugi, Chihiro
    Ishibashi, Keiichiro
    Yoshida, Hiroshi
    Ishida, Hideyuki
    Yamaguchi, Satoru
    Kuramochi, Hidekazu
    Fukazawa, Atsuko
    Sonoda, Hiromichi
    Yoshimatsu, Kazuhiko
    Matsuda, Akihisa
    Hasegawa, Suguru
    Sakamoto, Kazuhiro
    Otsuka, Toshiaki
    Koda, Keiji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2021, 26 (01) : 111 - 117
  • [7] Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)
    Hiroshi Matsuoka
    Takeshi Yamada
    Ryo Ohta
    Yoichiro Yoshida
    Tatsuyuki Watanabe
    Makoto Takahashi
    Chihiro Kosugi
    Atsuko Fukazawa
    Hidekazu Kuramochi
    Akihisa Matsuda
    Hiromichi Sonoda
    Hiroshi Yoshida
    Suguru Hasegawa
    Kazuhiro Sakamoto
    Toshiaki Otsuka
    Keiji Hirata
    Keiji Koda
    International Journal of Clinical Oncology, 2022, 27 : 1859 - 1866
  • [8] Biweekly TAS-102 and bevacizumab as third-line chemotherapy for advanced or recurrent colorectal cancer: a phase II, multicenter, clinical trial (TAS-CC4 study)
    Matsuoka, Hiroshi
    Yamada, Takeshi
    Ohta, Ryo
    Yoshida, Yoichiro
    Watanabe, Tatsuyuki
    Takahashi, Makoto
    Kosugi, Chihiro
    Fukazawa, Atsuko
    Kuramochi, Hidekazu
    Matsuda, Akihisa
    Sonoda, Hiromichi
    Yoshida, Hiroshi
    Hasegawa, Suguru
    Sakamoto, Kazuhiro
    Otsuka, Toshiaki
    Hirata, Keiji
    Koda, Keiji
    INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2022, 27 (12) : 1859 - 1866
  • [9] The combination of TAS-102 and bevacizumab as the third line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study)
    Kamiyama, H.
    Yoshida, Y.
    Yoshida, H.
    Kosugi, C.
    Ishibashi, K.
    Ihara, K.
    Takahashi, M.
    Kuramochi, H.
    Fukazawa, A.
    Sonoda, H.
    Yoshimatsu, K.
    Matsuda, A.
    Yamaguchi, S.
    Ishida, H.
    Hasegawa, S.
    Yamada, T.
    Sakamoto, K.
    Koda, K.
    ANNALS OF ONCOLOGY, 2018, 29 : 157 - 157
  • [10] Chemotherapy rechallenge or reintroduction, regorafenib, and TAS-102 for metastatic pretreated colorectal cancer patients: a propensity score analysis of treatment beyond the second line (PROSERpINA Study)
    Calegari, M.
    Zurlo, I.
    Basso, M.
    Orlandi, A.
    Bensi, M.
    Camarda, F.
    Di Stefano, B.
    Vivolo, R.
    Pozzo, C.
    Sperduti, I.
    Bria, E.
    Salvatore, L.
    Tortora, G.
    ANNALS OF ONCOLOGY, 2019, 30
12345